Mikrogen GmbH today announced that it has acquired the assets & technologies of Lophius Biosciences GmbH. Combining Mikrogen’s expertise in diagnostics and automation with Lophius’ technology for pathogen-specific immune stimulation will enable novel diagnostic solutions for infectious diseases and complement the Mikrogen portfolio. Mikrogen will expand operations by taking over the entire Lophius team and Lophius’ laboratories in BioPark Regensburg. In the future, the Lophius-developed in vitro diagnostic kit T-Track® CMV will be marketed by Mikrogen. By measuring CMV-specific cell-mediated immunity, T-Track® CMV adds an additional dimension to anti-CMV treatment decision-making in transplantation. T-Track® CMV complements the currently used CMV viral load tests, empowering clinicians to make personalized treatment decisions.…